SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases.
Formula:
C29H35N7OS
Target:
MAPK|||NOD-like Receptor (NLR)
* VAT and and shipping costs not included. Errors and price changes excepted
